Arix Bioscience (Arix) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high riskreturn profile of early-stage biotech investing. Arix minimises risk through its expert investment team and with portfolio diversification, sourced via its extensive network and partners. An experienced board protects the interests of Arix’s shareholders. Arix’s latest published Net Asset Value (NAV) of £232m (1H’19) includes 17 portfolio companies (PCs) into which Arix has invested ca.£135m since launch in 2016. The net cash position at 31 December 2019 is forecast at ca.£48m.
19 Feb 2020
With high risk can come high reward
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
With high risk can come high reward
Arix Bioscience (Arix) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high riskreturn profile of early-stage biotech investing. Arix minimises risk through its expert investment team and with portfolio diversification, sourced via its extensive network and partners. An experienced board protects the interests of Arix’s shareholders. Arix’s latest published Net Asset Value (NAV) of £232m (1H’19) includes 17 portfolio companies (PCs) into which Arix has invested ca.£135m since launch in 2016. The net cash position at 31 December 2019 is forecast at ca.£48m.